Maynard Um
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Lowered to $83 at BofA Securities
-
-
-
-
-
-
-
CRISPR Therapeutics' (CRSP) BEAM Risto-Cel Data Competitive - Citizens
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on CRISPR Therapeutics (CRSP)
-
-
-
-
-
-
-
CRISPR presents preclinical data for gene therapy targeting rare disorder
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) Misses Q2 EPS by 100c
-
-
-
-
-
-
-
Chardan: 'We think CRSP's emergence as a credible player in the space could thus drive further valuation upside'
-
-
-
-
-
-
-
Verve Therapeutics takeover has 'positive readthrough' for gene editing space - BMO Capital
-
418,488 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

